Financial Performance - The company's operating revenue for Q3 2021 was CNY 4,528,141,625.96, representing an increase of 8.12% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 75,396,481, a decrease of 8.63% year-on-year[4] - The basic earnings per share (EPS) decreased by 20.83% to CNY 0.19 from CNY 0.25 in the same period last year[4] - Total operating revenue for the period reached ¥13,002,322,197.61, compared to ¥11,403,022,961.83 in the previous period, reflecting a significant increase[21] - Net profit for the period was ¥225,412,641.24, compared to ¥211,946,770.60 in the previous period, showing a growth in profitability[23] - The total comprehensive income attributable to the parent company was CNY 228,203,202.40, an increase from CNY 211,882,888.10 in the previous period[24] - Basic and diluted earnings per share were both CNY 0.59, down from CNY 0.61 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 9,587,575,906.38, reflecting a growth of 13.67% compared to the end of the previous year[5] - The company's total assets increased to ¥9,587,575,906.38 from ¥8,434,883,342.25, indicating strong asset growth[20] - Total liabilities rose to ¥7,047,272,242.19 from ¥6,028,634,871.80, reflecting an increase in financial obligations[19] - Current liabilities reached ¥5,815,299,887.25, including short-term borrowings of ¥3,344,974,411.97 and accounts payable of ¥1,591,374,526.41[31] - Total liabilities were reported at ¥6,028,634,871.80, with non-current liabilities at ¥213,334,984.55[32] - Shareholders' equity totaled ¥2,406,248,470.45, with retained earnings of ¥1,098,667,059.56[32] Cash Flow - The cash flow from operating activities showed a net outflow of CNY 376,999,100, a decrease of 7.50% compared to the same period last year[4] - Cash inflow from operating activities totaled CNY 13,934,872,693.87, compared to CNY 12,199,499,798.07 in the previous period, representing an increase of approximately 14.2%[26] - Cash outflow from operating activities was CNY 14,311,871,826.50, up from CNY 12,550,194,101.61, leading to a net cash flow from operating activities of CNY -376,999,132.63[27] - The ending balance of cash and cash equivalents was CNY 373,952,346.20, down from CNY 354,059,041.08 in the previous period[28] - The company reported a decrease in cash and cash equivalents of CNY -99,824,238.31 for the period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,584[11] - Xiamen Mediken Technology Co., Ltd. holds 35.53% of shares, totaling 138,030,674 shares[11] - The company has a total of 138,030,674 unrestricted shares held by its top shareholders[11] - The company's financial performance and shareholder structure indicate a concentration of ownership, with the top shareholder holding over 35%[11] Legal Matters - The company has initiated legal actions to recover losses amounting to ¥2,310 million due to breaches of contract related to its subsidiary Chengdu Hechuang[14] - Chengdu Hechuang has filed a lawsuit seeking compensation of ¥39,697,300 and interest from Guizhou Mingrun Construction Engineering Co., Ltd.[15] - The company is involved in ongoing legal proceedings regarding guarantees and debts related to its subsidiary, impacting its financial position[13] - The company is actively pursuing recovery of debts through court actions, reflecting a strategic focus on financial recovery[14] Asset Management - The company reported a 65.35% increase in credit impairment losses, attributed to longer collection periods from medical institution clients due to increased sales in regions like Sichuan, Jiangxi, and Hainan[9] - The company’s contract liabilities increased by 115.42% to CNY 40,039,000, primarily due to increased prepayments for medical equipment[9] - The company’s intangible assets increased by 49.40% to CNY 169,168,100, mainly due to the acquisition of land use rights for a project[9] - Inventory levels increased to ¥2,205,183,924.97 from ¥2,028,122,409.74, suggesting potential growth in sales or production[18] Research and Development - The company reported a research and development expense of ¥2,289,641.11, down from ¥2,742,498.28 in the previous period, indicating a reduction in R&D investment[21] Accounting and Standards - The report indicates that the third-quarter financial results were not audited[33] - The company has implemented new leasing standards affecting the recognition of right-of-use assets and lease liabilities[33]
鹭燕医药(002788) - 2021 Q3 - 季度财报